Overview
CRBU market data
Price History
CRBU price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.59 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.38 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,189.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.38 – $3.54 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $159.7M · P/B 1.22 · P/S 14.25.
Company News
B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5Benzinga · Aug 14, 2026, 6:25 PM
Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M EstimateBenzinga · Aug 13, 2026, 8:24 PM
8-K filing — Caribou Biosciences, Inc. (CRBU)SEC EDGAR · Aug 13, 2026, 8:07 PM
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceGlobenewswire Inc · Jun 29, 2026, 12:15 PM
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual MeetingGlobenewswire Inc · Jun 11, 2026, 12:15 PM
Caribou Biosciences Reports Longer Follow Up Data For Ongoing CaMMouflage Phase 1 Trial Of CB-011, Off-The-Shelf BCMA-Targeted CAR-T Cell Therapy, Being Evaluated For r/r MMBenzinga · Jun 11, 2026, 12:02 PM